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Background
CCR5 regulation appears important in Th1 cell recruit-
ment to sites of inflammation/infection. HIV- and CMV-
specific CD4+ T-cells are CCR5+. Maraviroc, a CCR5-
receptor blocker licensed for HIV treatment, is associated
with an increased incidence of upper respiratory tract and
Herpes infections.
Methods
We investigated changes in CCR5+CD4+ and CD8+ T-cell
subsets, plasmacytoid dendritic cells (PDC) and antigen-
specific CD4+ cells in HIV (R5-tropic)-infected subjects
given SCH532706 with ritonavir (/r) for 10 days, fol-
lowed by a 15-day "washout" (day 11–25), and com-
mencing combination antiretroviral therapy (cART) on
day 25. Median decline in plasma HIV-RNA (VL) after 10
days of SCH532706/r vs. cART was -1.5 and -1.75 log10
copies/mL (p = 0.7, respectively. CD4+ cells specific for
Mycobacteria tuberculosis and avium (M.TB, MAI),
cytomegalovirus (CMV), Herpes simplex (HSV), HIV Gag,
CCR5+ cell subsets, and PDC were measured at days 1, 3,
10 (phase 1); 20, 25 (phase 2); and 25, 28, 35 on cART
(phase 3). Changes were analysed using the Mann-Whit-
ney test. Changes in CCR5+ T-cell subsets were assessed by
area-under-the-curve comparisons.
Summary of results
Ten males, with median 242 CD4+ (range 93–551), 783
CD8+ (range 353–1115) T-cells/μL, VL 4.5 log10 copies/
mL (range 3.8–5.7), were enrolled. At baseline, 20% of
CD4+ and 50% of CD8+ T-cells were CCR5+; CD4+ cells
specific for M.TB, MAI, CMV, HSV, HIV Gag were 0.45%,
5.7%, 5.0%, 2.3% and 1.75%, respectively. Median
changes in CD4+ T-cells during phases 1, 2, 3 were +16, -
26, +28 cells/μL, respectively (1 vs. 3: p = 0.7); CD8+ T-
cell changes were +91, -142, -71, respectively (1 vs. 3: p =
0.7). Relative to baseline, changes in CCR5+CD4+ T-cells
for phases 1, 2, 3 were +22%, -24% and +24%, respec-
tively (1 vs.3 p = 0.7). In contrast, CCR5+CD8+ T-cell
changes were +33%, -13% and -10%, respectively (signif-
icant for phases 1 vs. 2 and 1 vs. 3; both p = 0.01). PDC
increased during phase 1 compared to phases 2 (p = 0.02)
and 3 (p = 0.04). Equivalent declines in percentages of
M.TB-, CMV-, HSV-, and Gag-specific CD4+ cells occurred
during phases 1 and 3. MAI-specific CD4+ cells declined
on cART vs. SCH532706/r (p = 0.037).
Conclusion
CD4+ T-cell increases were modest on SCH532706/r and
cART. CCR5+CD8+ T-cells and PDC increased substan-
tially during receipt of the CCR5-antagonist, but not
cART, suggesting alterations in trafficking due to CCR5
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blockade. Declines in CMV, HSV and HIV Gag responses
were equivalent during receipt of SCH523706/r and sub-
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